Neutrophil elastase activated near-infrared two-region fluorescent carbon dots and application thereof in diagnosis of inflammatory bowel disease

By developing neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots, the problem of early non-invasive diagnosis of inflammatory bowel disease was solved by using near-infrared fluorescence imaging technology, and high specificity and sensitivity monitoring of the inflammatory sites of IBD were achieved , provides a safe and accurate diagnosis method.

CN118924920AActive Publication Date: 2024-11-12HEFEI UNIV OF TECH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410967881.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-12
Estimated Expiration
2044-07-18

AI Technical Summary

Technical Problem

Existing diagnostic methods for inflammatory bowel disease (IBD) are invasive and inaccurate, lacking non-invasive and rapid early detection methods, resulting in delayed diagnosis and difficult treatment.

Method used

Develop a neutrophil elastase-activated near-infrared second-zone fluorescent carbon dot (OPDG-PFA@PEI) to specifically respond to changes in neutrophil elastase through near-infrared fluorescence imaging technology to achieve non-invasiveness of early IBD diagnosis. This carbon dot is designed with a two-step reaction design through solvent-thermal/surface covalent bond modification, which has good water solubility and biosafety, and can stably release strong NIR-II fluorescence signals under 808nm excitation.

Benefits of technology

Achieve specific monitoring of elastase activity of neutrophils, provides non-invasive diagnostic evaluation of early IBD, has good biocompatibility and deep tissue imaging capabilities, reduces light scattering, improves diagnostic accuracy and Security.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924920A_ABST
    Figure CN118924920A_ABST
Patent Text Reader

Abstract

The invention discloses a neutrophil elastase activated near-infrared two-region fluorescent carbon dot and application thereof in diagnosis of inflammatory bowel diseases. The neutrophil elastase activated near-infrared two-region fluorescent carbon dot is obtained by combining a carbon dot synthesized by a solvothermal method with pentafluoropropionic anhydride through a covalent bond. The carbon dot disclosed by the invention can perform specific and sensitive response on neutrophil elastase with high biocompatibility in cells and in vivo, shows a strong NIR-II fluorescence signal, and can be used for real-time imaging of noninvasive diagnosis evaluation of early inflammatory bowel diseases; and a potential method is provided for developing a clinical non-invasive early inflammatory bowel disease diagnosis technology.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of nano material preparation and biomedicine, and specifically relates to a neutrophil elastase activated near-infrared second-zone fluorescent carbon dot and its application in the diagnosis of inflammatory bowel disease. Background Art

[0002] Inflammatory bowel disease (IBD) is a common chronic inflammatory disease of the gastrointestinal tract, including Crohn's disease (CD) and ulcerative colitis (UC). Its etiology is complex and is actually a complex disease caused by genetic, environmental, microbial and immune factors. In the past few decades, the incidence of inflammatory bowel disease has gradually increased. Early diagnosis and treatment are very important for patients with inflammatory bowel disease (IBD). Recent studies have shown that the diagnosis of IBD is often delayed, and this delay increases the risk of intestinal surgery. Currently, clinical diagnosis is mainly performed through endoscopic surgery. Compared with traditional examination methods, endoscopy has the advantage of being more intuitive, but endoscopy is invasive and may cause serious side effects. Therefore, for accurate clinical diagnosis and drug treatment, rapid and effective methods for detecting relevant biomarkers are highly needed for non-invasive diagnosis of early IBD.

[0003] Neutrophil elastase (NE) is a serine protease that is usually present in monocytes, T cells, and mast cells. It plays an important role in chronic inflammation and acute responses to infection and injury. It is a well-known inflammatory persistence factor and a promising prognostic biomarker. Excessive activation and release of NE not only degrades the extracellular matrix, increases tissue permeability, and promotes the infiltration and chemotaxis of neutrophils to the site of inflammation, but also releases inflammatory factors to promote inflammatory responses, thereby inducing a variety of inflammation-related diseases. Elastase expression in neutrophils is directly related to IBD, and NE is highly expressed in the inflammatory sites of IBD patients. Therefore, in situ monitoring of NE activity at the inflammatory sites of IBD patients is helpful for the clinical diagnosis or treatment of early IBD.

[0004] Carbon dots (CDs) are an emerging class of optical materials with particular applications in optoelectronic devices, catalysis, detection, and bioimaging. Due to their convenient synthetic procedures and effectively tunable chemical structures, utilizing CDs with bright NIR-II emission as standard imaging agents in the near-infrared second region (NIR-II) imaging window may usher in a new era of disease detection and surgical visualization. Summary of the invention

[0005] Inspired by the advantages of near-infrared fluorescence bioimaging of IBD-related biomarkers NE and CDs, the purpose of the present invention is to develop a neutrophil elastase-activated NIR-II fluorescent carbon dot (OPDG-PFA@PEI) that specifically responds to changes in NE content through near-infrared fluorescence imaging to achieve non-invasive diagnosis of early IBD.

[0006] In order to achieve the above object, the present invention adopts the following technical scheme:

[0007] The method for synthesizing neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots provided by the present invention comprises the following steps:

[0008] Step 1, o-phenylenediamine and glutathione are dissolved in formamide and dispersed uniformly by ultrasonication, the mixed solution is transferred to a polytetrafluoroethylene-lined autoclave for solvothermal reaction, and then the obtained reaction product is dialyzed and dried to obtain carbon dots, which are recorded as OPDG;

[0009] Step 2: The N,N-dimethylformamide solution of OPDG obtained in step 1 is mixed with pentafluoropropionic anhydride to obtain neutrophil elastase-activated near-infrared zone II fluorescent carbon dots, which are recorded as OPDG-PFA. The obtained OPDG-PFA dichloromethane solution is fully mixed with the PEI aqueous solution by probe ultrasound to improve the stability of OPDG-PFA in the aqueous solution, and then dried by rotary evaporation to obtain OPDG-PFA@PEI.

[0010] Preferably, in step 1, the mass ratio of o-phenylenediamine to glutathione is 10.8-108 mg:1.5-15 mg.

[0011] Preferably, in step 1, the solvent thermal reaction conditions are: reacting at 140-180° C. for 8-12 hours.

[0012] Preferably, in step 1, the dialysis is to dilute the obtained reaction product with pure water 3 to 5 times, pour it into a 500 to 1000 Da dialysis bag, and dialyze it at room temperature for 24 to 48 hours, and change the water in the dialysis system every 2 to 4 hours. The formamide solvent and molecules not involved in the reaction are removed by dialysis, and OPDG is obtained by rotary evaporation after the dialysis is completed. The purpose of rotary evaporation is to remove water molecules to prevent water molecules from hydrolyzing pentafluoropropionic anhydride in the next reaction.

[0013] Preferably, the preparation method of OPDG-PFA in step 2 is: dissolving OPDG in N,N-dimethylformamide and uniformly dispersing by ultrasonication, adding triethylamine at room temperature, and then adding pentafluoropropionic anhydride under ice bath conditions, and the resulting mixture is shaken at 30-40°C for 1-4h, and then rotary evaporated to obtain OPDG-PFA. Wherein, the mass ratio of OPDG, triethylamine and pentafluoropropionic anhydride is 3.73-37.3mg: 2.02-20.2mg: 6.2-62mg. The purpose of rotary evaporation is to remove pentafluoropropionic anhydride and DMF solvent that do not participate in the reaction.

[0014] Preferably, in step 2, the mass ratio of OPDG-PFA to PEI is 3-30 mg:9-90 mg, the time of emulsification by probe ultrasound is 10-30 min, and OPDG-PFA@PEI is obtained after rotary evaporation and drying. The purpose of rotary evaporation and drying is to remove the dichloromethane solvent.

[0015] The neutrophil elastase-activated near-infrared zone II fluorescent carbon dots prepared according to the above method have the following characteristics: they are designed and synthesized through a two-step reaction of solvent thermal / surface covalent bond modification, the procedure is simple, and the cost of reaction precursors is low; their radial size is 100-120 nm, and they have good water solubility and stability; they have good biosafety and bioavailability at the cellular and animal levels; they can maintain good stability under continuous excitation at 808 nm; they can specifically identify neutrophil elastase and release a strong NIR-II fluorescence signal.

[0016] The emission wavelength of the neutrophil elastase-activated near-infrared zone II fluorescent carbon dots prepared in the present invention can reach 1000-1100 nm. After oral administration, OPDG-PFA@PEI will be specifically activated by the neutrophil elastase highly expressed in the inflammatory site, showing a strong NIR-II fluorescence signal. The non-invasive diagnosis and evaluation of early IBD can be achieved by monitoring the NIR-II fluorescence imaging of neutrophil elastase activity.

[0017] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0018] 1. The present invention adopts a two-step reaction of solvothermal / surface covalent bond modification to design and synthesize OPDG-PFA@PEI. The emission center of the obtained water-soluble carbon dots is formed by covalent bonding of conjugated carbon cores. The synthesis procedure is simple and the cost of reaction precursors is low.

[0019] 2. The OPDG-PFA@PEI prepared in the present invention has good biocompatibility and bioavailability.

[0020] 3. The emission wavelength of the OPDG-PFA@PEI prepared in the present invention can reach 1091 nm, which can effectively penetrate superficial tissues and reach deeper tissue layers, and the light scattering phenomenon in the tissue is weak, thereby reducing image blur caused by light scattering.

[0021] 4. The OPDG-PFA@PEI prepared in the present invention will be specifically activated by neutrophil elastase highly expressed in the inflammatory site, showing a strong NIR-II fluorescence signal. The non-invasive diagnosis and evaluation of early IBD can be achieved by monitoring the NIR-II fluorescence imaging of neutrophil elastase activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 The schematic diagram of the synthesis of the neutrophil elastase-activated near-infrared zone II fluorescent carbon dots of the present invention is shown in FIG.

[0023] Figure 2 Transmission electron micrographs of OPDG ((a) in the figure) and OPDG-PFA@PEI ((b) in the figure) nanoparticles prepared in Example 1.

[0024] Figure 3 These are NIR-II fluorescence imaging images of OPDG and OPDG-PFA@PEI prepared in Example 1.

[0025] Figure 4 This is the fluorescence spectrum (808nm excitation) of OPDG and OPDG-PFA@PEI prepared in Example 1.

[0026] Figure 5 This is a diagram showing the cytotoxicity experiment of OPDG-PFA@PEI prepared in Example 1.

[0027] Figure 6 This is the experimental picture of cell NIR-II fluorescence imaging of OPDG-PFA@PEI prepared in Example 1.

[0028] Figure 7 This is a comparison chart of the results of quantitative analysis of the cell NIR-II fluorescence signal intensity of OPDG-PFA@PEI prepared in Example 1.

[0029] Figure 8 This is a statistical chart of the laser stability of OPDG and OPDG-PFA@PEI prepared in Example 1.

[0030] Fig. 9 This is a statistical graph of the fluorescence response of OPDG-PFA@PEI prepared in Example 1 to different enzymes and related species.

[0031] Fig.10This is a NIR-II fluorescence imaging experiment diagram of a mouse in supine position for in vivo drug delivery imaging of OPDG-PFA@PEI prepared in Example 1.

[0032] Fig.11 This is a comparison chart of the results of quantitative analysis of the NIR-II fluorescence signal intensity of the abdomen of mice in supine position for in vivo drug delivery imaging of OPDG-PFA@PEI prepared in Example 1.

[0033] Fig.12 This is a NIR-II fluorescence imaging experiment of mouse colon tissue administered with OPDG-PFA@PEI prepared in Example 1.

[0034] Fig.13 These are statistical graphs of the routine IBD assessment experiment in mice using OPDG-PFA@PEI drug administration imaging prepared in Example 1. Figure (a) shows the weight change of mice, Figure (b) shows the colon length of mice, and Figures (c to f) are comparison graphs of the levels of MPO, IL-1β, IL-6, and TNF-α in colon tissue homogenates, respectively. DETAILED DESCRIPTION

[0035] In order to make the above-mentioned purposes, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail in combination with the embodiments below. The following content is only an example and explanation of the concept of the present invention. The technicians in the relevant technical field make various modifications or supplements to the specific embodiments described or replace them in a similar manner. As long as they do not deviate from the concept of the invention or exceed the scope defined by the claims, they should all fall within the protection scope of the present invention.

[0036] Example 1

[0037] In this example, neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots were prepared as follows:

[0038] (1) Preparation of carbon dot OPDG: 108 mg of o-phenylenediamine and 15 mg of glutathione were dissolved in 10 mL of formamide and ultrasonicated for 10 min until the solution was clear and transparent. The mixed solution was transferred to a polytetrafluoroethylene-lined autoclave for solvothermal reaction at a reaction temperature of 180 °C and a reaction time of 12 h. After cooling to room temperature, three volumes of pure water were added for dilution, and the product was washed in 1.0 L of deionized water using a dialysis bag (500 Da) for 24 h. The dialysis system was replaced with water every 2 h. Finally, the OPDG aqueous solution was completely evaporated using a rotary evaporator, and then placed in a vacuum drying barrel overnight to completely evaporate the water, and further dispersed in DMF (concentration of 18.65 mg / mL) and stored at 4 °C.

[0039] (2) Preparation of neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots OPDG-PFA@PEI: Take a DMF solution containing 37.3 mg of OPDG, add 20 mg of triethylamine at room temperature, ultrasonicate for 1 min to fully mix the system, and slowly add 62 mg of pentafluoropropionic anhydride in an ice bath. The reaction mixture is shaken at 37°C for 3 to 4 h, and the DMF and pentafluoropropionic anhydride that do not participate in the reaction in the OPDG-PFA solution are completely evaporated using a rotary evaporator to obtain OPDG-PFA. Take 30 mg of OPDG-PFA and dissolve it in 6 mL of dichloromethane, and add 27 mL of an aqueous solution containing 90 mg of PEI. Use probe ultrasonic emulsification, the ultrasonic time is 10 min, and the ultrasonic power is 50%. The mixture is evaporated by a rotary evaporator at room temperature to obtain OPDG-PFA@PEI. Disperse OPDG-PFA@PEI in deionized water to obtain a dispersion with a concentration of 5 mg / mL, and store it in the dark.

[0040] Figure 2 The transmission electron microscope images of OPDG and OPDG-PFA@PEI obtained in Example 1 are characterized by dropping the aqueous dispersions of OPDG and OPDG-PFA@PEI onto the transmission electron microscope copper grid, drying them, and observing them under a transmission electron microscope. From the image, it can be seen that the material presents a spherical structure, with an OPDG diameter of about 10 nm and an OPDG-PFA@PEI diameter of 100 to 120 nm.

[0041] Figure 3 This is the NIR-II fluorescence imaging of 1 mg / mL aqueous solution of OPDG and OPDG-PFA@PEI obtained in Example 1 under 808 nm wavelength excitation light. It can be seen from the figure that OPDG shows a strong NIR-II fluorescence signal, and the fluorescence signal of OPDG-PFA@PEI after modification of the elastase specific recognition group is significantly weakened. This shows that the modification of pentafluoropropionic anhydride can weaken the NIR-II fluorescence intensity of OPDG.

[0042] Figure 4 The fluorescence spectra of 1 mg / mL aqueous solution of OPDG and OPDG-PFA@PEI obtained in Example 1 under 808 nm excitation light are shown in the figure. It can be seen from the figure that the emission wavelength of the prepared OPDG and OPDG-PFA@PEI can reach 1091 nm. The NIR-II fluorescence signal of OPDG-PFA@PEI is significantly lower than that of OPDG.

[0043] Figure 5 The cytotoxicity test diagram of OPDG-PFA@PEI obtained in Example 1 is as follows: 100 μL (1×10 5 ) of NCM460 cells and incubate at 37°C for 24 h. Figure 5 Add different concentrations of OPDG-PFA@PEI and incubate at 37°C for 24h. After the incubation, add 20μL MTT (5mg / mL) to each well and incubate in the incubator for 4h. Finally, aspirate the supernatant and add 150μL DMSO to each well to dissolve the formazan. Incubate at 37°C in the dark for 10min and measure the absorbance at 490nm. It can be seen from the figure that when the concentration of OPDG-PFA@PEI reaches 100μg / mL, the survival rate of NCM460 cells is still higher than 80%, indicating that the material has good biosafety and bioavailability.

[0044] Figure 6 The cell imaging experiment of OPDG-PFA@PEI obtained in Example 1 is shown in Figure 1. The characterization method is as follows: 100 μL (1×10 5 ) RAW264.7 cells were incubated at 37°C for 12 h before the experiment. RAW264.7 cells were divided into 7 groups (n=3 per group), and the experimental method for each group was as follows:

[0045] (1) Blank group: no treatment, OPDG-PFA@PEI (0.5 mg / mL) was added; (2) + Sivelestat group: Sivelestat (10 μM) was added, cultured at 37°C for 3 h, and then OPDG-PFA@PEI (0.5 mg / mL) was added; (3) - Sivelestat group: Sivelestat was not added, and OPDG-PFA@PEI (0.5 mg / mL) was directly added; (4) Sivelestat group: LPS (20 μg / mL) and Sivelestat (10 μM) were added, cultured at 37°C for 3 h, and then OPDG-PFA@PEI (0.5 mg / mL) was added; (5) 1 h group: Sivelestat was added LPS (20 μg / mL), 10 μM was added after culturing at 37°C for 1 h, and OPDG-PFA@PEI (0.5 mg / mL) was added after culturing at 37°C for 3 h; (5) 5 h group: LPS (20 μg / mL) was added, 10 μM was added after culturing at 37°C for 5 h, and OPDG-PFA@PEI (0.5 mg / mL) was added after culturing at 37°C for 3 h; (5) 8 h group: LPS (20 μg / mL) was added, 10 μM was added after culturing at 37°C for 8 h, and OPDG-PFA@PEI (0.5 mg / mL) was added after culturing at 37°C for 3 h;

[0046] After the material was added, the cells were incubated at 37°C for 30 minutes, and near-infrared images were collected using an InGaAs camera with a 900nm long-pass filter under 808nm excitation. It can be seen from the figure that after RAW264.7 cells were incubated with OPDG-PFA@PEI, the fluorescence intensity of inflammatory cells increased significantly.

[0047] Figure 7 for Figure 6 The experimental diagram for quantifying fluorescence intensity is characterized by reading the fluorescence intensity using image J. It can be seen from the figure that the fluorescence intensity of Raw264.7 cells inhibited by sivelestat is almost the same as that of the blank control group, and the fluorescence intensity of Raw264.7 cells induced by LPS for 5 hours is the highest, indicating that OPDG-PFA@PEI can specifically recognize NE and release NIR-II fluorescence signals by breaking the amide bond.

[0048] Figure 8 The laser stability experimental diagram of OPDG and OPDG-PFA@PEI obtained in Example 1 is characterized by taking 100 μL of OPDG and OPDG-PFA@PEI (0.5 mg / mL) aqueous dispersion and adding it to a 96-well plate, continuously exciting with 808 nm excitation light for 10 min, and collecting near-infrared images under an InGaAs camera with a 900 nm long-pass filter at 0 min, 2 min, 4 min, 6 min, 8 min, and 10 min. It can be seen from the figure that after continuous excitation at 808 nm for 10 min, the fluorescence intensity of OPDG and OPDG-PFA@PEINIR-II did not significantly weaken, and had good laser stability.

[0049] Fig. 9 The fluorescence response experimental diagram of OPDG-PFA@PEI obtained in Example 1 to different enzymes and related species is shown in the figure. The characterization method is as follows: 500 μg / mL OPDG-PFA@PEI was added to PBS buffer (pH 7.4) with various related species (200 μM) and enzymes (750 pg / mL), and 20 groups (n=3 per group) were set up: (1) blank; (2) vitamin C; (3) cysteine; (4) glutathione; (5) glucose; (6) glycine; (7) histidine; (8) leucine; (9) H 2 S; (10)Fe 3+ ; (11) Cu 2+ ; (12) Mg 2+ ; (13) Zn 2+ ; (14) HClO; (15) H 2 O 2 ; (16) bovine albumin; (17) γ-glutamyl transferase; (18) β-galactosidase; (19) esterase; (20) NE. Incubate at 37℃ in the dark for 30min, and collect near-infrared images with an InGaAs camera using a 900nm long-pass filter under 808nm excitation. It can be seen from the figure that OPDG-PFA@PEI shows high specificity and sensitivity to NE.

[0050] Fig.10The experimental diagram of near-infrared fluorescence imaging of OPDG-PFA@PEI in Balb / C female mice obtained in Example 1 is characterized by: 3.5g DSS was dissolved in 100mL deionized water to prepare a 3.5% DSS solution for constructing an IBD mouse model. Balb / C female mice were randomly divided into 3 groups (n=3 per group), and the experimental method of each group was as follows: (1) Control: fed with normal water for 7 days; (2) DSSDay4: 3.5% DSS solution was used instead of normal water for 4 days as an early IBD mouse model; (2) DSSDay7: 3.5% DSS solution was used instead of normal water for 7 days as a late IBD mouse model. All mice used for in vivo imaging were fed with jelly 24h before image acquisition to reduce the interference of mouse feed on gastrointestinal imaging. After the modeling was completed, the three groups of mice were given OPDG-PFA@PEI (100mg / kg) by gavage. 4 hours after oral administration, NIR-II images were collected under 808nm excitation using a 900nm long-pass filter under an InGaAs camera. It can be seen from the figure that strong NIR-II fluorescence signals were detected in the abdomen of DSS Day4 and DSSDay7 mice, while relatively low fluorescence signals were detected in the abdomen of control mice.

[0051] Fig.11 This is a fluorescence intensity quantification experiment diagram of NIR-II fluorescence imaging of OPDG-PFA@PEI in Balb / C female mice obtained in Example 1. The characterization method is: using image J to read the intensity of the mouse abdomen. It can be seen from the figure that the NIR-II fluorescence signal of the abdomen of DSSDay4 and DSSDay7 mice is significantly higher than that of the control group mice. This shows that OPDG-PFA@PEI can recognize NE with high specificity and monitor early IBD through NIR-II fluorescence imaging.

[0052] Fig.12The experimental figure of OPDG-PFA@PEI obtained in Example 1 in the colon tissue of Balb / C female mice is characterized by: 3.5g DSS was dissolved in 100mL deionized water to prepare a 3.5% DSS solution for the construction of IBD mouse model. Balb / C female mice were randomly divided into 3 groups (n=3 per group), and the experimental method of each group was as follows: (1) Control: normal water feeding for 7 days; (2) DSSDay4: 3.5% DSS solution was used instead of normal water for feeding for 4 days as an early IBD mouse model; (3) DSSDay7: 3.5% DSS solution was used instead of normal water for feeding for 7 days as a late IBD mouse model. All mice used for in vivo imaging were fed with jelly 24h before image acquisition to reduce the interference of mouse feed on gastrointestinal imaging. After the modeling was completed, the three groups of mice were given OPDG-PFA@PEI (100mg / kg) by gavage. Four hours after oral administration, the mice were killed, and the colon of the mice was taken out and NIR-II images were collected under 808nm excitation using a 900nm long-pass filter under an InGaAs camera. It can be seen from the figure that strong NIR-II fluorescence signals were detected in the colon tissues of DSSDay4 and DSSDay7 mice, and relatively low fluorescence signals were detected in the colon tissues of the control mice. This shows that OPDG-PFA@PEI can highly specifically identify NE in the inflammatory sites of early and late IBD mice, and can thus be used for non-invasive diagnosis and evaluation of early IBD.

[0053] Fig.13 This is a routine evaluation experiment of IBD in Balb / C female mice. Figure (a) shows the weight change of mice, Figure (b) shows the length of the mouse colon, and Figures (c-f) show the characterization method of the colon tissue homogenate pro-inflammatory level evaluation experiment: weigh 0.5g of colon, add 10mL of PBS7.4, and keep at 2-8℃. The sample was fully homogenized by hand. Centrifuge at 2500rpm for 20min, collect the supernatant, and obtain the tissue homogenate. The commercial enzyme-linked immunosorbent assay kit was used to detect MPO activity and the levels of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. It can be seen from the figure that the weight of mice on DSS 4 days and DSS 7 days decreased significantly, and the colon length was shortened. The levels of MPO, TNF-α, IL-1β, and IL-6 in the colon tissue homogenate were higher than those in the control group, indicating that the mice had IBD symptoms.

[0054] In summary, the carbon dots of the present invention can respond specifically and sensitively to neutrophil elastase with high biocompatibility in cells and in vivo, showing strong NIR-II fluorescence signals, and can be used for real-time imaging of noninvasive diagnosis and evaluation of early inflammatory bowel disease, providing a potential method for the development of clinical noninvasive diagnosis technology for early inflammatory bowel disease.

[0055] The above description is only an exemplary embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for synthesizing neutrophil elastase-activated near-infrared zone II fluorescent carbon dots, characterized in that: The following steps are involved: Step 1, o-phenylenediamine and glutathione are dissolved in formamide and dispersed uniformly by ultrasonication, the mixed solution is transferred to an autoclave for solvothermal reaction, and then the obtained reaction product is dialyzed and dried to obtain carbon dots, which are recorded as OPDG; Step 2, the N,N-dimethylformamide solution of OPDG obtained in step 1 is mixed with pentafluoropropionic anhydride to obtain neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots, which are recorded as OPDG-PFA; The obtained OPDG-PFA dichloromethane solution and PEI aqueous solution were fully mixed by probe ultrasound to improve the stability of OPDG-PFA in the aqueous solution, and then dried by rotary evaporation to obtain OPDG-PFA@PEI.

2. The method for synthesizing neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots according to claim 1, characterized in that: In step 1, the mass ratio of o-phenylenediamine to glutathione is 10.8-108 mg:1.5-15 mg.

3. The method for synthesizing neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots according to claim 1, characterized in that: In step 1, the solvent thermal reaction conditions are: reacting at 140-180° C. for 8-12 hours.

4. The method for synthesizing neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots according to claim 1, characterized in that: In step 1, the dialysis is to dilute the obtained reaction product with pure water by 3 to 5 times, pour it into a 500 to 1000 Da dialysis bag, and dialyze it at room temperature for 24 to 48 hours, and change the water in the dialysis system every 2 to 4 hours.

5. The method for synthesizing neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots according to claim 1, characterized in that: The preparation method of OPDG-PFA in step 2 is: dissolve OPDG in N,N-dimethylformamide and disperse it evenly by ultrasonication, add triethylamine at room temperature, and then add pentafluoropropionic anhydride under ice bath conditions, and the resulting mixture is reacted on a shaking table at 30-40°C for 1-4h, and then rotary evaporated to obtain OPDG-PFA.

6. The method for synthesizing neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots according to claim 5, characterized in that: The mass ratio of OPDG, triethylamine and pentafluoropropionic anhydride is 3.73-37.3 mg: 2.02-20.2 mg: 6.2-62 mg.

7. The method for preparing neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots according to claim 1, characterized in that: In step 2, the mass ratio of OPDG-PFA to PEI is 3-30 mg:9-90 mg.

8. Neutrophil elastase-activatable near-infrared second-zone fluorescent carbon dots prepared by the synthesis method according to any one of claims 1 to 7.

9. The neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots according to claim 8, characterized in that: The emission wavelength of the fluorescent carbon dots can reach 1000-1100 nm.

10. An application of the neutrophil elastase-activated near-infrared second-zone fluorescent carbon dots according to claim 8 or 9, characterized in that: Used for preparing preparations for specifically identifying neutrophil elastase for diagnosing inflammatory bowel disease.

Citation Information

Patent Citations

  • Hetero-element doped red light carbon dot for detecting multiple metal ions and preparation method and application thereof

    CN115044370A

  • Superbright chemiluminescent probes for detection and imaging

    CN117769549A

  • Imaging agents for imaging protease activity and uses thereof

    US20140249468A1

  • Antibodies for treatment and diagnosis of inflammatory bowel disease

    US20190062414A1